Does the media prefer NRC or HCAT?

In the previous week, National Research and National Research both had 2 articles in the media. Health Catalyst's average media sentiment score of 1.34 beat National Research's score of 0.75 indicating that Health Catalyst is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment National Research 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Health Catalyst 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to EVH or HCAT?

In the previous week, Evolent Health and Evolent Health both had 2 articles in the media. Health Catalyst's average media sentiment score of 1.34 beat Evolent Health's score of 0.17 indicating that Health Catalyst is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolent Health 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Health Catalyst 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HCAT or AMWL?

In the previous week, Health Catalyst had 1 more articles in the media than American Well. MarketBeat recorded 2 mentions for Health Catalyst and 1 mentions for American Well. Health Catalyst's average media sentiment score of 1.34 beat American Well's score of 0.72 indicating that Health Catalyst is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Health Catalyst 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive American Well 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor HCAT or OPRX?

In the previous week, OptimizeRx had 5 more articles in the media than Health Catalyst. MarketBeat recorded 7 mentions for OptimizeRx and 2 mentions for Health Catalyst. Health Catalyst's average media sentiment score of 1.34 beat OptimizeRx's score of 0.52 indicating that Health Catalyst is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Health Catalyst 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OptimizeRx 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer HCAT or DH?

In the previous week, Health Catalyst had 1 more articles in the media than Definitive Healthcare. MarketBeat recorded 2 mentions for Health Catalyst and 1 mentions for Definitive Healthcare. Health Catalyst's average media sentiment score of 1.34 beat Definitive Healthcare's score of 0.00 indicating that Health Catalyst is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Health Catalyst 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Definitive Healthcare 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Health Catalyst (HCAT) Competitors

$1.72 -0.17 (-8.99%)

Closing price 04:00 PM Eastern

Extended Trading

$1.72 +0.01 (+0.29%)

As of 05:18 PM Eastern

Compare

HCAT vs. NRC, EVH, AMWL, OPRX, and DH

Should you buy Health Catalyst stock or one of its competitors? Health Catalyst's main competitors and comparable companies include National Research (NRC), Evolent Health (EVH), American Well (AMWL), OptimizeRx (OPRX), and Definitive Healthcare (DH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does Health Catalyst compare to National Research?

National Research (NASDAQ:NRC) and Health Catalyst (NASDAQ:HCAT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

In the previous week, National Research and National Research both had 2 articles in the media. Health Catalyst's average media sentiment score of 1.34 beat National Research's score of 0.75 indicating that Health Catalyst is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
National Research	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Health Catalyst	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.3% of National Research shares are held by institutional investors. Comparatively, 85.0% of Health Catalyst shares are held by institutional investors. 9.2% of National Research shares are held by insiders. Comparatively, 19.4% of Health Catalyst shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

National Research has a net margin of 4.18% compared to Health Catalyst's net margin of -90.61%. National Research's return on equity of 164.26% beat Health Catalyst's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
National Research	4.18%	164.26%	14.67%
Health Catalyst	-90.61%	-1.83%	-0.80%

National Research has higher earnings, but lower revenue than Health Catalyst. Health Catalyst is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
National Research	$137.39M	3.57	$11.60M	$0.25	86.32
Health Catalyst	$311.14M	0.42	-$177.97M	-$3.68	N/A

National Research presently has a consensus price target of $26.00, suggesting a potential upside of 20.48%. Health Catalyst has a consensus price target of $2.45, suggesting a potential upside of 42.44%. Given Health Catalyst's higher probable upside, analysts clearly believe Health Catalyst is more favorable than National Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
National Research	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Health Catalyst	1 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

National Research has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, Health Catalyst has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market.

Summary

National Research beats Health Catalyst on 8 of the 15 factors compared between the two stocks.

How does Health Catalyst compare to Evolent Health?

Evolent Health (NYSE:EVH) and Health Catalyst (NASDAQ:HCAT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

Evolent Health has a net margin of -24.08% compared to Health Catalyst's net margin of -90.61%. Health Catalyst's return on equity of -1.83% beat Evolent Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evolent Health	-24.08%	-4.27%	-1.06%
Health Catalyst	-90.61%	-1.83%	-0.80%

Health Catalyst has lower revenue, but higher earnings than Evolent Health. Evolent Health is trading at a lower price-to-earnings ratio than Health Catalyst, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolent Health	$1.88B	0.22	-$534.51M	-$4.57	N/A
Health Catalyst	$311.14M	0.42	-$177.97M	-$3.68	N/A

In the previous week, Evolent Health and Evolent Health both had 2 articles in the media. Health Catalyst's average media sentiment score of 1.34 beat Evolent Health's score of 0.17 indicating that Health Catalyst is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evolent Health	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Health Catalyst	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Evolent Health has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market. Comparatively, Health Catalyst has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market.

Evolent Health presently has a consensus target price of $5.96, indicating a potential upside of 64.99%. Health Catalyst has a consensus target price of $2.45, indicating a potential upside of 42.44%. Given Evolent Health's stronger consensus rating and higher possible upside, equities research analysts clearly believe Evolent Health is more favorable than Health Catalyst.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolent Health	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.63
Health Catalyst	1 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

85.0% of Health Catalyst shares are held by institutional investors. 1.5% of Evolent Health shares are held by company insiders. Comparatively, 19.4% of Health Catalyst shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Health Catalyst beats Evolent Health on 10 of the 15 factors compared between the two stocks.

How does Health Catalyst compare to American Well?

Health Catalyst (NASDAQ:HCAT) and American Well (NYSE:AMWL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

Health Catalyst currently has a consensus target price of $2.45, suggesting a potential upside of 42.44%. American Well has a consensus target price of $9.50, suggesting a potential downside of 27.80%. Given Health Catalyst's stronger consensus rating and higher probable upside, analysts clearly believe Health Catalyst is more favorable than American Well.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Catalyst	1 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
American Well	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

American Well has lower revenue, but higher earnings than Health Catalyst. American Well is trading at a lower price-to-earnings ratio than Health Catalyst, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Catalyst	$311.14M	0.42	-$177.97M	-$3.68	N/A
American Well	$249.32M	0.87	-$95.70M	-$4.77	N/A

85.0% of Health Catalyst shares are held by institutional investors. Comparatively, 56.1% of American Well shares are held by institutional investors. 19.4% of Health Catalyst shares are held by insiders. Comparatively, 12.8% of American Well shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

American Well has a net margin of -35.75% compared to Health Catalyst's net margin of -90.61%. Health Catalyst's return on equity of -1.83% beat American Well's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Health Catalyst	-90.61%	-1.83%	-0.80%
American Well	-35.75%	-30.12%	-22.30%

Health Catalyst has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market. Comparatively, American Well has a beta of 1.71, suggesting that its share price is 71% more volatile than the broader market.

In the previous week, Health Catalyst had 1 more articles in the media than American Well. MarketBeat recorded 2 mentions for Health Catalyst and 1 mentions for American Well. Health Catalyst's average media sentiment score of 1.34 beat American Well's score of 0.72 indicating that Health Catalyst is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Health Catalyst	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
American Well	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Health Catalyst beats American Well on 12 of the 16 factors compared between the two stocks.

How does Health Catalyst compare to OptimizeRx?

Health Catalyst (NASDAQ:HCAT) and OptimizeRx (NASDAQ:OPRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

In the previous week, OptimizeRx had 5 more articles in the media than Health Catalyst. MarketBeat recorded 7 mentions for OptimizeRx and 2 mentions for Health Catalyst. Health Catalyst's average media sentiment score of 1.34 beat OptimizeRx's score of 0.52 indicating that Health Catalyst is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Health Catalyst	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OptimizeRx	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OptimizeRx has lower revenue, but higher earnings than Health Catalyst. Health Catalyst is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Catalyst	$311.14M	0.42	-$177.97M	-$3.68	N/A
OptimizeRx	$109.43M	1.31	$5.13M	$0.23	33.04

85.0% of Health Catalyst shares are owned by institutional investors. Comparatively, 76.5% of OptimizeRx shares are owned by institutional investors. 19.4% of Health Catalyst shares are owned by company insiders. Comparatively, 7.5% of OptimizeRx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Health Catalyst has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market. Comparatively, OptimizeRx has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

Health Catalyst currently has a consensus price target of $2.45, indicating a potential upside of 42.44%. OptimizeRx has a consensus price target of $11.43, indicating a potential upside of 50.38%. Given OptimizeRx's stronger consensus rating and higher probable upside, analysts plainly believe OptimizeRx is more favorable than Health Catalyst.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Catalyst	1 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
OptimizeRx	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

OptimizeRx has a net margin of 4.66% compared to Health Catalyst's net margin of -90.61%. OptimizeRx's return on equity of 9.44% beat Health Catalyst's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Health Catalyst	-90.61%	-1.83%	-0.80%
OptimizeRx	4.66%	9.44%	7.11%

Summary

OptimizeRx beats Health Catalyst on 11 of the 16 factors compared between the two stocks.

How does Health Catalyst compare to Definitive Healthcare?

Health Catalyst (NASDAQ:HCAT) and Definitive Healthcare (NASDAQ:DH) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

Definitive Healthcare has a net margin of -72.28% compared to Health Catalyst's net margin of -90.61%. Definitive Healthcare's return on equity of 3.55% beat Health Catalyst's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Health Catalyst	-90.61%	-1.83%	-0.80%
Definitive Healthcare	-72.28%	3.55%	1.63%

Health Catalyst presently has a consensus target price of $2.45, indicating a potential upside of 42.44%. Definitive Healthcare has a consensus target price of $1.47, indicating a potential upside of 45.69%. Given Definitive Healthcare's higher probable upside, analysts plainly believe Definitive Healthcare is more favorable than Health Catalyst.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Catalyst	1 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
Definitive Healthcare	3 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	1.90

85.0% of Health Catalyst shares are held by institutional investors. Comparatively, 98.7% of Definitive Healthcare shares are held by institutional investors. 19.4% of Health Catalyst shares are held by company insiders. Comparatively, 17.1% of Definitive Healthcare shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Health Catalyst had 1 more articles in the media than Definitive Healthcare. MarketBeat recorded 2 mentions for Health Catalyst and 1 mentions for Definitive Healthcare. Health Catalyst's average media sentiment score of 1.34 beat Definitive Healthcare's score of 0.00 indicating that Health Catalyst is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Health Catalyst	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Definitive Healthcare	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Definitive Healthcare has lower revenue, but higher earnings than Health Catalyst. Definitive Healthcare is trading at a lower price-to-earnings ratio than Health Catalyst, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Catalyst	$311.14M	0.42	-$177.97M	-$3.68	N/A
Definitive Healthcare	$241.52M	0.45	-$138.93M	-$1.60	N/A

Health Catalyst has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market. Comparatively, Definitive Healthcare has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

Summary

Definitive Healthcare beats Health Catalyst on 9 of the 17 factors compared between the two stocks.

Get Health Catalyst News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HCAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HCAT vs. The Competition

Export

Metric	Health Catalyst	Healthcare Technology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$129.45M	$1.74B	$7.20B	$13.10B
Dividend Yield	N/A	3.89%	2.53%	13.00%
P/E Ratio	-0.47	20.86	274.58	25.69
Price / Sales	0.42	89.26	644.00	85.88
Price / Cash	0.85	31.68	76.31	52.02
Price / Book	0.50	6.20	10.44	6.32
Net Income	-$177.97M	-$18.66M	$3.49B	$359.73M
7 Day Performance	-0.58%	1.06%	0.51%	1.35%
1 Month Performance	12.42%	1.48%	-3.38%	-3.68%
1 Year Performance	-39.65%	-17.21%	16.04%	5.56%

Health Catalyst Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HCAT Health Catalyst	4.4648 of 5 stars	$1.72 -9.0%	$2.45 +42.4%	-35.9%	$129.45M	$311.14M	N/A	1,200	Positive News
NRC National Research	2.5704 of 5 stars	$21.97 -1.5%	$26.00 +18.4%	+43.6%	$499.43M	$137.39M	87.81	357	News Coverage
EVH Evolent Health	3.0593 of 5 stars	$3.93 -4.3%	$5.96 +52.0%	-55.8%	$442.63M	$1.88B	N/A	4,200
AMWL American Well	2.5074 of 5 stars	$13.64 -1.7%	$9.50 -30.4%	+104.2%	$225.77M	$218.53M	N/A	562
OPRX OptimizeRx	3.7705 of 5 stars	$7.58 -2.9%	$11.43 +50.8%	-60.1%	$142.81M	$109.43M	32.96	100	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HCAT) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Health Catalyst (HCAT) Competitors

HCAT vs. NRC, EVH, AMWL, OPRX, and DH

How does Health Catalyst compare to National Research?

Summary

How does Health Catalyst compare to Evolent Health?

Summary

How does Health Catalyst compare to American Well?

Summary

How does Health Catalyst compare to OptimizeRx?

Summary

How does Health Catalyst compare to Definitive Healthcare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCAT vs. The Competition

Health Catalyst Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Health Catalyst (HCAT) Competitors

HCAT vs. NRC, EVH, AMWL, OPRX, and DH

How does Health Catalyst compare to National Research?

Does the media prefer NRC or HCAT?

Do institutionals & insiders have more ownership in NRC or HCAT?

Is NRC or HCAT more profitable?

Which has higher valuation and earnings, NRC or HCAT?

Do analysts rate NRC or HCAT?

Which has more risk and volatility, NRC or HCAT?

Summary

How does Health Catalyst compare to Evolent Health?

Is EVH or HCAT more profitable?

Which has stronger earnings and valuation, EVH or HCAT?

Does the media refer more to EVH or HCAT?

Which has more volatility and risk, EVH or HCAT?

Do analysts recommend EVH or HCAT?

Do insiders & institutionals have more ownership in EVH or HCAT?

Summary

How does Health Catalyst compare to American Well?

Do analysts rate HCAT or AMWL?

Which has better earnings & valuation, HCAT or AMWL?

Do institutionals & insiders have more ownership in HCAT or AMWL?

Is HCAT or AMWL more profitable?

Which has more risk and volatility, HCAT or AMWL?

Does the media refer more to HCAT or AMWL?

Summary

How does Health Catalyst compare to OptimizeRx?

Does the media favor HCAT or OPRX?

Which has higher valuation and earnings, HCAT or OPRX?

Do insiders & institutionals have more ownership in HCAT or OPRX?

Which has more volatility and risk, HCAT or OPRX?

Do analysts recommend HCAT or OPRX?

Is HCAT or OPRX more profitable?

Summary

How does Health Catalyst compare to Definitive Healthcare?

Is HCAT or DH more profitable?

Do analysts prefer HCAT or DH?

Do insiders and institutionals believe in HCAT or DH?

Does the media prefer HCAT or DH?

Which has better valuation and earnings, HCAT or DH?

Which has more risk & volatility, HCAT or DH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCAT vs. The Competition

Health Catalyst Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools